新冠病毒感染后，使用糖萼膳食补充剂进行4个月治疗对内皮糖萼和血管功能的影响。
Effects of 4-month treatment with glycocalyx dietary supplement on endothelial glycocalyx and vascular function after COVID-19 infection.
作者信息
Pavlidis George, Kountouri Aikaterini, Katogiannis Konstantinos, Thymis John, Nikolaou Panagiota Efstathia, Chania Christina, Karalis John, Kostelli Gabriella, Michalopoulou Eleni, Katsanaki Eleni, Parissis John, Vink Hans, Long Robert, Tsiodras Sotirios, Lambadiari Vaia, Ikonomidis Ignatios
机构信息
2nd Department of Cardiology, Attikon University Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.
2nd Propaedeutic Department of Internal Medicine, Research Unit and Diabetes Center, Attikon University Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.
出版信息
Eur J Clin Invest. 2025 Apr 24:e70058. doi: 10.1111/eci.70058.
BACKGROUND
Coronavirus disease 2019 (COVID-19) has been associated with impaired endothelial and vascular function. We investigated whether intervention with glycocalyx dietary supplement (GDS), containing glucosamine sulfate and fucoidan, improves endothelial glycocalyx and vascular function after COVID-19 infection.
METHODS
Fifty-seven convalescent patients 14 days after mild-to-moderate COVID-19 infection managed in an outpatient setting were randomized to receive GDS (n = 29) or placebo (n = 28) for 4 consecutive months. We measured at baseline and at 4 months: (a) perfused boundary region (PBR) of the sublingual microvessels with a diameter range of 4-25 μm, as a marker of endothelial glycocalyx integrity, (b) pulse wave velocity and augmentation index, (c) coronary flow reserve using Doppler echocardiography, and (d) malondialdehyde and protein carbonyls as oxidative stress markers.
RESULTS
Four months after treatment, patients who received GDS showed a greater reduction in PBR 4-25 μm (-6.8% vs. -1.3%), pulse wave velocity (-13.2% vs. -3%), augmentation index (-28.5% vs. -2.5%), malondialdehyde (-26% vs. -2.9%), protein carbonyls (-31.3% vs. -1%) and a greater increase in coronary flow reserve (12.9% vs. 1.6%) compared to placebo (p < .05). In the GDS group, the reduction in PBR 4-25 μm was associated with the corresponding decrease in pulse wave velocity (r = .31, p = .047), malondialdehyde, and protein carbonyls, as well as with the increase in coronary flow reserve (r = -.59, p = .008) at follow-up. Post-treatment, none of the patients under GDS reported post-COVID symptoms compared to 21.4% of the patients under placebo.
CONCLUSION
Four-month treatment with GDS may improve endothelial glycocalyx and vascular function after COVID-19 infection.
CLINICAL TRIAL REGISTRATION
URL: https://www.
CLINICALTRIALS
gov. Unique identifier: NCT05185934.
背景
2019冠状病毒病（COVID-19）与内皮和血管功能受损有关。我们研究了使用含有硫酸葡萄糖胺和岩藻依聚糖的糖萼膳食补充剂（GDS）进行干预是否能改善COVID-19感染后的内皮糖萼和血管功能。
方法
57例在门诊接受治疗的轻度至中度COVID-19感染后14天的康复患者被随机分为两组，连续4个月接受GDS（n = 29）或安慰剂（n = 28）治疗。我们在基线和4个月时测量：（a）直径范围为4 - 25μm的舌下微血管的灌注边界区域（PBR），作为内皮糖萼完整性的标志物；（b）脉搏波速度和增强指数；（c）使用多普勒超声心动图测量冠状动脉血流储备；（d）丙二醛和蛋白质羰基作为氧化应激标志物。
结果
治疗4个月后，与安慰剂组相比，接受GDS治疗的患者在4 - 25μm的PBR降低幅度更大（-6.8%对-1.3%）、脉搏波速度降低幅度更大（-13.2%对-3%）、增强指数降低幅度更大（-28.5%对-2.5%）、丙二醛降低幅度更大（-26%对-2.9%）、蛋白质羰基降低幅度更大（-31.3%对-1%），冠状动脉血流储备增加幅度更大（12.9%对1.6%）（p < 0.05）。在GDS组中，4 - 25μm的PBR降低与随访时脉搏波速度相应降低（r = 0.31，p = 0.047）、丙二醛和蛋白质羰基降低以及冠状动脉血流储备增加（r = -0.59，p = 0.008）相关。治疗后，接受GDS治疗的患者均未报告COVID后症状，而接受安慰剂治疗的患者中有21.4%报告了该症状。
结论
GDS治疗4个月可能改善COVID-19感染后的内皮糖萼和血管功能。
临床试验注册
网址：https://www.
临床试验
gov。唯一标识符：NCT05185934。
Zotero 插件